Tentarix biotherapeutics emerges with $50 million series a

San diego & vancouver, british columbia--(business wire)--biotechnology company tentarix biotherapeutics lp today announced a $50 million series a investment co-led by versant ventures and samsara biocapital. “the advent of technologies to produce high-precision biologics to engage multiple disease targets represents a major advance,” said president and ceo paul grayson, a venture partner at versant ventures. “this financing allows us to develop multiple programs for oncology and autoimmune dis
FATE Ratings Summary
FATE Quant Ranking